Expertise in
5
conditions

Stephan Brand

HOCH Health Ostschweiz
Sankt Gallen, SG, CH 
Expertise in
5
conditions
HOCH Health Ostschweiz
Sankt Gallen, SG, CH 

Overview

Stephan Brand practices practicing medicine in Sankt Gallen, Switzerland.

Mr. Brand is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Viral Gastroenteritis, Colitis, Hemorrhagic Proctocolitis, Endoscopy, and Colonoscopy.

He is actively involved in clinical research, co-authoring 78 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

HOCH Health Ostschweiz
Sankt Gallen, SG, Switzerland
Other Locations
Wetzikon, ZH, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
Prospective, Non-interventional, Observational Study in Patients With IBD Receiving IV or SC Vedolizumab Therapy to Observe Route of Administration Choices and Outcomes (VARIETY-Switzerland)
Prospective, Non-interventional, Observational Study in Patients With IBD Receiving IV or SC Vedolizumab Therapy to Observe Route of Administration Choices and Outcomes (VARIETY-Switzerland)
Enrollment Status: Completed
Publish Date: December 29, 2025
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Multi-center, Multi-national, Randomized, Double-blind, Placebo Controlled, Parallel Group, Phase IIa Study to Evaluate the Efficacy, Safety and Tolerability of an Anthocyanin-rich Extract (ACRE) in Patients With Ulcerative Colitis
A Multi-center, Multi-national, Randomized, Double-blind, Placebo Controlled, Parallel Group, Phase IIa Study to Evaluate the Efficacy, Safety and Tolerability of an Anthocyanin-rich Extract (ACRE) in Patients With Ulcerative Colitis
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Drug: Standardized anthocyanin-rich extract
Study Phase: Phase 2
View 6 Less Clinical Trials

78 Total Publications

Anti-Integrin αvβ6 Autoantibodies Distinguish Ulcerative Colitis From Crohn's Disease With High Diagnostic Accuracy and Outperform ANCA and ASCA Status: A Prospective Cross-Sectional Study.
Anti-Integrin αvβ6 Autoantibodies Distinguish Ulcerative Colitis From Crohn's Disease With High Diagnostic Accuracy and Outperform ANCA and ASCA Status: A Prospective Cross-Sectional Study.
Journal: Alimentary pharmacology & therapeutics
Published: June 12, 2026

Frequently Asked Questions about Stephan Brand

Is Stephan Brand a top-rated expert for Viral Gastroenteritis?

MediFind is an objective health platform that identifies experts based on real-world data. Stephan Brand is classified as an Advanced expert for Viral Gastroenteritis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Stephan Brand participate in research or clinical trials?

Yes. Stephan Brand has published 78 articles and abstracts on conditions like Viral Gastroenteritis. You can view a list of Stephan Brand's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Brand's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile